Korean J Dermatol.  2013 Jun;51(6):438-441.

Refractory Plaque Psoriasis Treated with a Combination of Etanercept and Low Dose Methotrexate

Affiliations
  • 1Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea. schul@jnu.ac.kr

Abstract

Etanercept has been proven to be highly effective to moderate severe plaque psoriasis. Alternative biologics or combination therapies of etanercept with other systemic agents have been recommended to patients who are unable to be controlled by etanercept monotherapy. A 50-year-old woman, who did not respond to conventional therapy of psoriasis for 9 years, was treated with etanercept at a schedule of 50 mg doses per week. Psoriatic lesions were remarkably improved within two weeks after etanercept monotherapy, but skin lesions aggravated again 8 weeks after treatment. Then, she was treated with 50 mg etanercept in combination with 5 mg methotrexate per week. Psoriatic lesions were successfully controlled by the combination therapy for 6 weeks, followed by etanercept monotherapy without relapse for the past 13 months. We report the first Korean case of refractory psoriasis, which could be successfully controlled by combination therapy of etanercept with low doses of methotrexate.

Keyword

Combination therapy; Etanercept; Methotrexate; Refractory plaque psoriasis

MeSH Terms

Appointments and Schedules
Biological Agents
Female
Humans
Immunoglobulin G
Methotrexate
Psoriasis
Receptors, Tumor Necrosis Factor
Recurrence
Skin
Etanercept
Biological Agents
Immunoglobulin G
Methotrexate
Receptors, Tumor Necrosis Factor
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr